$ELAN News

New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience

Elanco Animal Health Incorporated (ELAN) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Elanco Animal Health Incorporated (ELAN) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow

A Look At Elanco (ELAN) Valuation After Early Befrena Launch And Renewed Investor Optimism

Elanco (ELAN) Is Up 9.8% After Launching Befrena, Its Second USDA-Approved Pet Biologic

Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript

Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks

Elanco Launches Befrena As New Dermatology Driver For Undervalued Shares

3 Reasons to Sell ELAN and 1 Stock to Buy Instead

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market

Elanco Animal Health Rolls Out Befrena Monoclonal Antibody To Treat Anine Allergic, Atopic Dermatitis

5 Insightful Analyst Questions From Elanco’s Q1 Earnings Call

Elanco to Participate in Upcoming Investor Conferences

Elanco Animal Health Q1 Earnings Call Highlights

Elanco Animal Health (ELAN) Is Up 20.1% After Raising 2026 Guidance On Innovation-Led Growth

Citigroup Maintains Buy on Elanco Animal Health, Raises Price Target to $31

JP Morgan Maintains Overweight on Elanco Animal Health, Raises Price Target to $30

Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript

Elanco Animal Health Incorporated 2026 Q1 - Results - Earnings Call Presentation

Elanco (ELAN) Q1 2026 Earnings Transcript